| Backgroud Under the guidance of the basic theory of traditional Chinese medicine, Clinical application of combined Shenqi Siwutang Wulingsan treatment of chronic heart failure, Shenqi Siwutang close observation Wulingsan cardiopulmonary deficiency, blood stasis type of clinical efficacy in patients with CHF, and its effect on serum NT-proBNP levels. Method CHF patients to choose from March 2014 to March 2015 during the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Cardiovascular inpatient treatment,44 cases of cardiac function Ⅱ～Ⅳ grade. The method of completely randomized, divided into 22 cases of the treatment group and the control group 22 cases. Western medicine treatment control group basis, and western medicine treatment group on the basis of treatment plus Shenqi Siwutang together Wulingsan, Two weeks later observed. Three conventional laboratory tests, electrolytes, liver function, kidney function for security indicators to determine Shenqi Siwutang together Wulingsan whether the toxic side effects, Observation and analysis of TCM symptom scores before and after treatment in both groups, Lee’s failure score, clinical symptoms and clinical conditions, such as cardiac function, NT-proBNP in serum before and after treatment detection. Result After two weeks of treatment, The effective rate is 86.36%, the efficiency of the control group was 81.32%, Comparison of the two groups, the difference was not statistically significant (P> 0.05); Serum levels of NT-proBNP levels were decreased compared with before treatment, But the treatment group, serum NT-proBNP levels than the control group was significantly lower relative, with statistical significance (P<0.05). The difference between the different levels of serum NT-proBNP NYHA classification, the higher NYHA classification, higher serum NT-proBNP levels. Serum NT-proBNP levels and primary disease unrelated. After treatment, cardiac function, Lee’s integration was no significant difference in heart failure (P>0.05), TCM syndromes integral significantly after treatment (P<0.05). Conclusion ① Shenqi Siwutang together Wulingsan CHF patients can improve heart palpitations, shortness of breath, lassitude, edema, urine deficient and other clinical symptoms, reduced symptom scores, toxicity did not occur. ② Shenqi Siwutang Wulingsan together to some extent reduce the cardiopulmonary deficiency, blood stasis type of serum NT-proBNP levels in patients with CHF, objective proof of its efficacy.③ serum NT-proBNP is a specific marker of cardiac dysfunction, can be used as the evaluation shenqi Siwutang Wulingsan CHF combined clinical efficacy testing metrics.④Shenqi Siwutang Wulingsan combined treatment of CHF mechanism may inhibit the neuroendocrine system, thereby reducing serum NT-proBNP levels. |
PDF Full Text Request